GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Life Sciences Ltd (NSE:GLS) » Definitions » ROE % Adjusted to Book Value

Glenmark Life Sciences (NSE:GLS) ROE % Adjusted to Book Value : 2.95% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Glenmark Life Sciences ROE % Adjusted to Book Value?

Glenmark Life Sciences's ROE % for the quarter that ended in Sep. 2024 was 15.02%. Glenmark Life Sciences's PB Ratio for the quarter that ended in Sep. 2024 was 5.10. Glenmark Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was 2.95%.


Glenmark Life Sciences ROE % Adjusted to Book Value Historical Data

The historical data trend for Glenmark Life Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Life Sciences ROE % Adjusted to Book Value Chart

Glenmark Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - - 10.89 9.90 5.16

Glenmark Life Sciences Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.26 - 4.12 - 2.95

Competitive Comparison of Glenmark Life Sciences's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Life Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Life Sciences's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Life Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Glenmark Life Sciences's ROE % Adjusted to Book Value falls into.



Glenmark Life Sciences ROE % Adjusted to Book Value Calculation

Glenmark Life Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=21.07% / 4.08
=5.16%

Glenmark Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=15.02% / 5.10
=2.95%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glenmark Life Sciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Glenmark Life Sciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Life Sciences Business Description

Traded in Other Exchanges
Address
470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Glenmark Life Sciences Headlines

No Headlines